NO2718543T3 - - Google Patents

Info

Publication number
NO2718543T3
NO2718543T3 NO12800169A NO12800169A NO2718543T3 NO 2718543 T3 NO2718543 T3 NO 2718543T3 NO 12800169 A NO12800169 A NO 12800169A NO 12800169 A NO12800169 A NO 12800169A NO 2718543 T3 NO2718543 T3 NO 2718543T3
Authority
NO
Norway
Application number
NO12800169A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2718543T3 publication Critical patent/NO2718543T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO12800169A 2014-02-04 2012-06-13 NO2718543T3 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461965584P 2014-02-04 2014-02-04

Publications (1)

Publication Number Publication Date
NO2718543T3 true NO2718543T3 (ja) 2018-01-06

Family

ID=53777338

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12800169A NO2718543T3 (ja) 2014-02-04 2012-06-13

Country Status (8)

Country Link
US (1) US10167264B2 (ja)
EP (1) EP3102571B1 (ja)
JP (1) JP6257787B2 (ja)
CN (1) CN105980377B (ja)
DK (1) DK3102571T3 (ja)
ES (1) ES2667847T3 (ja)
NO (1) NO2718543T3 (ja)
WO (1) WO2015117547A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554318A (zh) * 2015-09-25 2017-04-05 正大天晴药业集团股份有限公司 氘代二苯基氨基嘧啶化合物
CN106554347B (zh) * 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
CN105461640B (zh) * 2015-12-02 2017-11-21 芷威（上海）化学科技有限公司 一种酪氨酸激酶抑制剂的制备方法
CN106146406A (zh) * 2016-02-23 2016-11-23 深圳市塔吉瑞生物医药有限公司 一种取代的二氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107344925B (zh) * 2016-05-04 2022-11-11 正大天晴药业集团股份有限公司 氘代二苯基氨基-三氟甲基嘧啶化合物
CN107088196A (zh) * 2017-02-27 2017-08-25 王涛 一种治疗骨质疏松症的药物组合物
WO2020257385A1 (en) * 2019-06-20 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659725T3 (es) * 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
CA2861010A1 (en) * 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
SG11201405692UA (en) * 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Salts of an epidermal growth factor receptor kinase inhibitor
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor

Also Published As

Publication number Publication date
EP3102571A4 (en) 2016-12-14
ES2667847T3 (es) 2018-05-14
WO2015117547A1 (en) 2015-08-13
US20170008856A1 (en) 2017-01-12
JP6257787B2 (ja) 2018-01-10
DK3102571T3 (en) 2018-05-07
JP2017505319A (ja) 2017-02-16
EP3102571A1 (en) 2016-12-14
EP3102571B1 (en) 2018-04-04
US10167264B2 (en) 2019-01-01
CN105980377A (zh) 2016-09-28
CN105980377B (zh) 2018-07-03

Similar Documents

Publication Publication Date Title
BR112014019923A2 (ja)
BR112014018750A2 (ja)
BR112014017614A2 (ja)
BR112014017625A2 (ja)
BR112014017592A2 (ja)
BR112014018862A2 (ja)
BR112014017659A2 (ja)
BR112014017646A2 (ja)
BR112014018745A2 (ja)
BR112014017638A2 (ja)
BR112014017607A2 (ja)
BR112014017609A2 (ja)
BR112014017644A2 (ja)
BR112014024756A2 (ja)
BR112014017647A2 (ja)
BR112014017618A2 (ja)
BR112014017652A2 (ja)
BR112014019416A2 (ja)
BR112014017621A2 (ja)
BR112014017622A2 (ja)
BR112014017623A2 (ja)
BR112014017641A2 (ja)
BR112014020594A2 (ja)
BR112014017732A2 (ja)
BR112014017667A2 (ja)